StockNews.com started coverage on shares of NeuroMetrix (NASDAQ:NURO – Free Report) in a research note released on Wednesday. The brokerage issued a sell rating on the medical device company’s stock.
NeuroMetrix Stock Performance
NASDAQ:NURO opened at $3.93 on Wednesday. NeuroMetrix has a 52 week low of $2.66 and a 52 week high of $5.96. The firm has a 50-day moving average price of $3.64 and a two-hundred day moving average price of $3.84. The firm has a market cap of $7.90 million, a price-to-earnings ratio of -0.63 and a beta of 2.28.
NeuroMetrix (NASDAQ:NURO – Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The medical device company reported ($0.74) EPS for the quarter. The business had revenue of $0.77 million for the quarter. NeuroMetrix had a negative net margin of 181.04% and a negative return on equity of 41.74%.
NeuroMetrix Company Profile
NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.
Featured Stories
- Five stocks we like better than NeuroMetrix
- Insider Trades May Not Tell You What You Think
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- Investing in the High PE Growth Stocks
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- How to Use the MarketBeat Stock Screener
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for NeuroMetrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix and related companies with MarketBeat.com's FREE daily email newsletter.